

The REDOXS® Circular




Congratulations to our colleagues in Kiel and Greifswald for enrolling the 1st two German patients into the REDOXS® Study!!! Glückwünsche!

Great job Eileen Campbell from London HSC & Laura Banici at Montreal General for enrolling your 1st patients since joining the REDOXS® team!

Keep those patients coming... Remember our goal is 2 pts/site/month.


Enrolment as of July 31, 2009

Canada








Site #	Institution 	July	Cumulative
1	Kingston General Hospital	1	63
2	St. Joseph's Healthcare	2	35
3	Ottawa General	5	97
4	Ottawa Civic	-	38
5	Vancouver General	-	19
6	Sacre-Coeur, Montreal	1	49
7	Maisonneuve-Rosemont	-	13
8	*Royal Victoria, Montreal	-	8
9	Royal Alexandra, Edmonton	1	17
11	Grey Nun's, Edmonton	-	12
13	Victoria General	1	4
14	London HSC	1	11
15	HSC Winnipeg	-	8
16	Queen Elizabeth II, Halifax	1	8
17	Sunnybrook, Toronto	-	2
18	St. Paul's, Vancouver	-	6
19	Montreal General	1	8
20	Enfant-Jesus, Quebec City	-	19
23	Royal Jubilee, Victoria	-	5
25	Mount Sinai, Toronto	2	18
29	St. Boniface, Winnipeg	-	-
32	University Hospital, London	1	3

* site on hold due to staffing issues

United States

Site #	Institution 	July	Cumulative
26	University of Colorado	1	10
27	Miami Valley, Ohio	-	2
28	Fletcher Allen, Vermont	-	4
30	University of Louisville	-	8
31	University of Texas	-	-

Europe

Site #	Institution	July	Cumulative
21	Liege, Belgium 	-	3
22	CHUV, Switzerland 	-	8
24	UZ Brussels, Belgium 	-	2
35	University Medical Center SH, Kiel 	1	1
36	University Medical Center SH, Lübeck 	-	-
37	EMA University, Greifswald 	1	1
38	Asklepios Klinik Hamburg-Altona 	-	-

Enrolment Totals:

Monthly Cumulative*

*Includes 80 from pilot

June 2009 **33** **542**

July 2009 **20** **562**



Interim Analysis

We are only 38 patients away from reaching the halfway mark of the study. With the enrolment of 600 patients just around the corner, we would like to remind sites to complete their data entry as soon as possible.

Current # enrolled = **562**
Current # locked charts = **472**
We require 600 locked charts for the interim analysis.

Restricted Enteral Formulas

Over the past couple of months we have noted a few REDOXS[©] Study patients have received Oxepa[®] while they are participating in the study. Oxepa[®] contains elevated levels of antioxidants and should NOT be administered to REDOXS[®] patients while they are on the study.



The following list of enteral formulas should NOT be given to REDOXS[©] patients because they contain elevated levels of glutamine, antioxidants, selenium, Vitamin A, C,E, beta-carotene, zinc or arginine:

- Vivonex Plus/T.E.N.
- Oxepa
- Perative
- Optimental
- Impact/Impact 1.5
- Peptamen AF
- Probiotics
- Glutamine supplements
- Pivot 1.5

Refer to the Administration of Study Supplements Manual (pg. 9-10) for further details. Contact the Project Leader if you have any questions about specific formulas.


Tips from the Data Management Team

Etiology of Shock

Please note the newly added option of "hemorrhagic" to the etiology of shock taxonomy.

Hypovolemic Shock—In cases where the patient is considered to be in hypovolemic shock, please determine the cause of the hypovolemia: Is it hemorrhagic in nature or due to something else?

If the cause is hemorrhagic, please select the corresponding option on the EDCS drop-down menu. If it is due to some other reason (e.g. dehydration), select the "other" option and enter "hypovolemia due to reason".



Distributive Shock—In cases where the patient is considered to be in distributive shock, you should determine the most responsible reason for the shock: Is the distributive shock primarily anaphylactic, neurogenic or septic in nature? Is there some other reason (e.g. drug overdose)?

Please ensure you choose the appropriate taxonomy option.

Primary ICU Admission Diagnosis

Please ensure you are entering the most responsible reason for a patient's admission to the ICU in Primary ICU Admission Diagnosis field.

For example, we have many patients with an admission diagnosis entered as "Respiratory Failure". Respiratory failure is a general diagnosis, we would like sites to seek the reason why the patient was in respiratory failure.

Micro Culture Results

If an organism sub species is NOT reported on a laboratory report please enter the organism into the EDCS as follows:

Species: *Species name on lab report*

Sub Species: *Other specify:*

Other: *Not Specified*

STUDY CHAIR

Daren Heyland
dkh2@queensu.ca

PROJECT LEADERS

Rupinder Dhaliwal
dhaliwar@kgh.kari.net
Janet Overvelde
overvelj@kgh.kari.net

DATA MANAGEMENT

Jennifer Korol
korolj@kgh.kari.net
Shawna Froese
froeses@kgh.kari.net

PROJECT ASSISTANTS

Suzanne Biro
biros@kgh.kari.net
Susan Campbell
campbes3@kgh.kari.net

Amendment to Pharmacy Procedures

Thanks to the site Pharmacists for their efforts in implementing the updated Pharmacy Procedures regarding the preparation of Parenteral Study Supplements. If you have not yet completed the implementation process, please do so as soon as possible and remember to forward the confirmation fax once this has been completed. Thank you!